Based thereon, they suggested that in future clinical ALL studies, cases with a cytogenetically evident KMT2A should not be evaluated together with KMT2A translocations anymore, but should be screened for the ETV6::RUNX1 fusion gene right away [60]. Here, RUNX1 is linked to acute lymphoblastic leukemia.